Make Better Decisions

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries
➤ Start Trial

or, See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Covington
McKinsey
UBS
Deloitte
QuintilesIMS
Chinese Patent Office
McKesson
Harvard Business School
AstraZeneca
Farmers Insurance

Generated: January 17, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,586,633

« Back to Dashboard

Which drugs does patent 8,586,633 protect, and when does it expire?

Patent 8,586,633 protects OMIDRIA and is included in one NDA.

This patent has twenty-two patent family members in fourteen countries.
Summary for Patent: 8,586,633
Title:Ophthalmologic irrigation solutions and method
Abstract: Solutions for perioperative intraocular application by continuous irrigation during ophthalmologic procedures are provided. These solutions include multiple agents that act to inhibit inflammation, inhibit pain, effect mydriasis (dilation of the pupil), and/or decrease intraocular pressure, wherein the multiple agents are selected to target multiple molecular targets to achieve multiple differing physiologic functions, and are included in dilute concentrations in a balanced salt solution carrier.
Inventor(s): Demopulos; Gregory A. (Mercer Island, WA), Palmer; Pamela Pierce (San Francisco, CA), Herz; Jeffrey M. (Mill Creek, WA)
Assignee: Omeros Corporation (Seattle, WA)
Application Number:13/420,456
Patent Claim Types:
see list of patent claims
Use; Composition; Formulation; Delivery;

Drugs Protected by US Patent 8,586,633

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Omeros OMIDRIA ketorolac tromethamine; phenylephrine hydrochloride SOLUTION;IRRIGATION 205388-001 May 30, 2014 RX Yes Yes ➤ Subscribe ➤ Subscribe Y ➤ Subscribe
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,586,633

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,173,707 Ophthalmologic irrigation solutions and method ➤ Subscribe
9,278,101 Ophthalmologic irrigation solutions and method ➤ Subscribe
9,585,895 Ophthalmologic irrigation solutions and method ➤ Subscribe
9,399,040 Ophthalmologic irrigation solutions and method ➤ Subscribe
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Patents Family Members for US Patent 8,586,633

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Slovenia 1534313 ➤ Subscribe
Portugal 1534313 ➤ Subscribe
Luxembourg 92923 ➤ Subscribe
Japan 2016014056 ➤ Subscribe
Japan 2016014055 ➤ Subscribe
Japan 2013216705 ➤ Subscribe
Japan 2011006475 ➤ Subscribe
Japan 2010132696 ➤ Subscribe
Japan 2006504661 ➤ Subscribe
Hungary S1500069 ➤ Subscribe
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving leading biopharmaceutical companies globally:

Fuji
Healthtrust
Moodys
Cerilliant
Teva
Daiichi Sankyo
Merck
Boehringer Ingelheim
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

botpot